Scarica l'app Stockscreener
60.62
0.28%
-0.155
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$60.77
Aprire:
$60.94
Volume 24 ore:
4.45M
Relative Volume:
0.32
Capitalizzazione di mercato:
$123.38B
Reddito:
$48.19B
Utile/perdita netta:
$7.06B
Rapporto P/E:
17.53
EPS:
3.4587
Flusso di cassa netto:
$15.30B
1 W Prestazione:
+8.23%
1M Prestazione:
+8.48%
6M Prestazione:
+31.88%
1 anno Prestazione:
+9.13%
Intervallo 1D:
$59.95
$61.45
Intervallo di 1 settimana:
$56.43
$62.05
Portata 52W:
$42.52
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Nome
Bristol Myers Squibb Co
Settore
Industria
Telefono
(609) 252-4621
Indirizzo
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, NVS, AZN
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
60.60 | 123.71B | 48.19B | 7.06B | 15.30B | 3.4587 |
|
LLY
Lilly Eli Co
|
1,031.92 | 935.00B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
238.66 | 574.95B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
224.56 | 394.59B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
NVS
Novartis Ag Adr
|
158.42 | 299.68B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
AZN
Astrazeneca Plc
|
193.78 | 291.47B | 58.07B | 9.40B | 9.87B | 3.0115 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Aggiornamento | UBS | Neutral → Buy |
| 2025-12-15 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-12-12 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-05 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Iniziato | Piper Sandler | Overweight |
| 2024-12-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-13 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Downgrade | Citigroup | Buy → Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-07-29 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Downgrade | Societe Generale | Buy → Hold |
| 2024-02-06 | Downgrade | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-11-15 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-02 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-07-10 | Iniziato | SVB Securities | Market Perform |
| 2023-06-28 | Iniziato | Daiwa Securities | Outperform |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-01-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Iniziato | Credit Suisse | Neutral |
| 2022-10-10 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-09-14 | Downgrade | Berenberg | Buy → Hold |
| 2022-06-03 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Underweight |
| 2021-12-17 | Iniziato | Goldman | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-01 | Downgrade | Argus | Buy → Hold |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Aggiornamento | Truist | Hold → Buy |
| 2020-11-16 | Aggiornamento | Societe Generale | Hold → Buy |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-11-06 | Downgrade | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2020-07-28 | Iniziato | Raymond James | Outperform |
| 2020-04-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-01-06 | Ripresa | Citigroup | Buy |
| 2019-12-13 | Aggiornamento | Argus | Hold → Buy |
| 2019-11-22 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-08-14 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-05-20 | Downgrade | Argus | Buy → Hold |
| 2019-05-03 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Ripresa | JP Morgan | Overweight |
| 2019-01-15 | Aggiornamento | Societe Generale | Sell → Buy |
| 2018-10-22 | Downgrade | Citigroup | Buy → Neutral |
Mostra tutto
Bristol Myers Squibb Co Borsa (BMY) Ultime notizie
Bristol-Myers Squibb stock rating reiterated by Bernstein at Market Perform - Investing.com India
Bristol-Myers Squibb: Solid Near-Term Execution and 2026 EPS Boost from Eliquis, but Limited Long-Term Visibility Supports Hold Rating - TipRanks
Assessing Bristol Myers Squibb (BMY) Valuation After Earnings Beat And Pipeline Optimism - Yahoo Finance UK
Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline Overview: Insights into 80+ Leading Companies and 100+ Novel Treatments | DelveInsight - GlobeNewswire Inc.
Guggenheim Raises its Price Target on Bristol-Myers Squibb Company (BMY) to $72 and Reiterates a Buy Rating - Finviz
Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence - Yahoo Finance Singapore
Bristol-Myers Squibb Stock Is On Sale: Smart Buy Or Value Trap You’ll Regret? - AD HOC NEWS
Bristol-Myers Squibb Stock: Dividend Giant Under Pressure or Deep-Value Setup? - AD HOC NEWS
Jim Cramer Discusses Bristol Myers's (BMY) Cobenfy Drug - Finviz
Jim Cramer Discusses Bristol Myers’s (BMY) Cobenfy Drug - Insider Monkey
Birmingham Capital Management Co. Inc. AL Reduces Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb (BMY) Returns To US$7.1b Trailing Profit Challenging Bearish Narratives - simplywall.st
Bristol-Myers Squibb stock price target raised to $72 by Guggenheim - Investing.com UK
Bristol-Myers Squibb stock price target raised to $60 by Wells Fargo - Investing.com UK
Bristol-Myers Squibb: A Dividend Gem With Hidden Upside In 2026 (NYSE:BMY) - Seeking Alpha
Bristol Myers Squibb (NYSE:BMY) Given New $64.00 Price Target at Citigroup - MarketBeat
Bristol-Myers Squibb stock price target raised to $72 by Guggenheim By Investing.com - Investing.com India
Bristol-Myers Squibb Co (NYSE:BMY) Tops Estimates - FXDailyReport.Com
Bristol-Myers Squibb Co (BMY) Stock Price Up 3.76% on Feb 6 - GuruFocus
Wells Fargo Raises Price Target for Bristol-Myers Squibb (BMY) | BMY Stock News - GuruFocus
Bristol-Myers Squibb Company (NYSE:BMY) Q4 2025 Earnings Call Transcript - Insider Monkey
Bristol-Myers Squibb Co. (BMY) PT Raised to $72 at Guggenheim - StreetInsider
BMS reports flat revenue growth for full-year 2025 - Pharmaceutical Technology
BMY Q4 Deep Dive: Growth Portfolio Offsets Legacy Pressure, Pipeline Readouts in Focus - Finviz
Bristol Myers Squibb stock gets positive readthrough from Bayer stroke data - Investing.com
Bristol-Myers Squibb (BMY) Exceeds Q4 Earnings Expectations - GuruFocus
Bristol-Myers Squibb (BMY) Surpasses Q4 Expectations, Sets Stron - GuruFocus
Bristol-Myers Squibb (BMY) Reports Strong Q4, Projects Robust Gr - GuruFocus
Why Bristol Myers Squibb Stock Topped the Market Today - Yahoo Finance
Bristol Myers (BMY) Maintains Positive Outlook Amid Stroke Treat - GuruFocus
Reiterating Buy on Bristol-Myers Squibb: Milvexian’s Validated FXIa Mechanism and Underappreciated Stroke Prevention Upside Support $65 Target - TipRanks
Bristol-Myers Squibb Co (BMY) Q4 2025 Earnings Call Highlights: Strong Growth in New Products ... By GuruFocus - Investing.com Canada
Bristol's Portfolio of Newer Therapies and Strong Late-Stage Pipeline Support a Wide Moat - morningstar.com
Bristol-Myers Squibb Co (BMY) Q4 2025 Earnings Call Highlights: - GuruFocus
Bristol-Myers Squibb (BMY) Surpasses Q4 Expectations and Raises Dividend - GuruFocus
Bristol Myers Earnings Reveal Struggling Legacy Drug Business. Why the Stock Is Rising. - Barron's
We're increasing our price target on Bristol Myers after earnings and guidance top forecasts - CNBC
BMS Beats Again Despite Eliquis and Cobenfy Disappointments - BioSpace
Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates - Finviz
Bristol Myers Stock Rises on Earnings. This Drug Portfolio Continues to Be a Drag. - Barron's
Bristol-Myers Squibb Q4 2025 slides: Growth portfolio offsets legacy declines - Investing.com
Bristol Myers posts modest Q4 growth, outlines cautious outlook - The Pharma Letter
Earnings call transcript: Bristol-Myers Squibb beats Q4 2025 forecasts By Investing.com - Investing.com India
Earnings call transcript: Bristol-Myers Squibb beats Q4 2025 forecasts - Investing.com
Bristol’s Outlook Tops Views as New Drugs Gain Momentum - bloomberg.com
Bristol Myers Squibb (NYSE:BMY) Issues FY 2026 Earnings Guidance - MarketBeat
Bristol Myers earnings beat amid blood thinner, cancer immunotherapy strength - Investing.com India
Bristol-Myers Squibb (NYSE:BMY) Reports Strong Q4 CY2025 - Finviz
Bristol Myers Squibb Co (NYSE:BMY) Beats Q4 2025 Earnings Estimates and Provides Strong 2026 Outlook - Chartmill
Bristol Myers: Q4 Earnings Snapshot - kens5.com
Bristol Myers earnings beat estimates amid cancer immunotherapy drug strength - Investing.com
Bristol Myers Squibb Co Azioni (BMY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.79%
1.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):